HIMS logo

Hims & Hers Health, Inc. Stock Price

NYSE:HIMS Community·US$8.4b Market Cap
  • 8 Narratives written by author
  • 12 Comments on narratives written by author
  • 1048 Fair Values set on narratives written by author

HIMS Share Price Performance

US$36.07
-15.17 (-29.61%)
US$26.82
Fair Value
US$36.07
-15.17 (-29.61%)
34.5% overvalued intrinsic discount
US$26.82
Fair Value
Price US$36.07
AnalystConsensusTarget US$26.82
AnalystHighTarget US$40.00
Deep_Insights US$173.02

HIMS Community Narratives

·
Fair Value US$26.82 34.5% overvalued intrinsic discount

Telehealth And Hormonal Health Will Transform Global Markets

12users have liked this narrative
0users have commented on this narrative
261users have followed this narrative
·
Fair Value US$40 9.8% undervalued intrinsic discount

Telemedicine And AI Integration Will Redefine Digital Healthcare

0users have liked this narrative
0users have commented on this narrative
28users have followed this narrative
Fair Value
·
Fair Value US$173.02 79.2% undervalued intrinsic discount

Hims & Hers Health Multidimensional Revenue Expansion

10users have liked this narrative
0users have commented on this narrative
43users have followed this narrative
US$173.02
79.2% undervalued intrinsic discount
Fair Value
Revenue
36.3% p.a.
Profit Margin
10%
Future PE
60x
Price in 2030
US$242.66
US$50.07
28.0% undervalued intrinsic discount
Fair Value
Revenue
37% p.a.
Profit Margin
6.05%
Future PE
26.92x
Price in 2031
US$70.16
US$86.09
58.1% undervalued intrinsic discount
Fair Value
Revenue
22% p.a.
Profit Margin
15%
Future PE
50x
Price in 2030
US$138.65
US$17.15
110.3% overvalued intrinsic discount
Profit Margin
1%
Future PE
20x
Price in 2029
US$28.59

Trending Discussion

Updated Narratives

HIMS logo

Hims & Hers Paves the Path to $1 Billion Quarterly Revenue in end of 2026

Fair Value: US$173.02 79.2% undervalued intrinsic discount
43 users have set this as their fair value
0 users have commented on this narrative
2 users have liked this narrative
HIMS logo

FY2025

Fair Value: US$29.21 23.5% overvalued intrinsic discount
5 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
HIMS logo

Long on HIMS

Fair Value: US$50.07 28.0% undervalued intrinsic discount
10 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

High growth potential with mediocre balance sheet.

1 Risk
1 Reward

Hims & Hers Health, Inc. Key Details

US$2.4b

Revenue

US$641.8m

Cost of Revenue

US$1.7b

Gross Profit

US$1.7b

Other Expenses

-US$13.2m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.057
72.92%
-0.56%
218.3%
View Full Analysis

About HIMS

Founded
n/a
Employees
2442
CEO
Andrew Dudum
WebsiteView website
www.hims.com

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.

Recent HIMS News & Updates

Narrative Update Jul 06

HIMS: Novo Partnership And Peptide Uncertainty Will Shape Future Profitability

The analyst price target for Hims & Hers Health has been raised from $35 to $40, with analysts pointing to improving alternative data around its GLP-1 offerings and peptide opportunity, while still highlighting uncertainties around subscriber retention and margin trends. Analyst Commentary Recent research around Hims & Hers Health points to a split view, with bullish analysts highlighting the company’s GLP-1 and peptide offerings as key drivers of interest, while more cautious voices are focused on execution risks around subscriber retention, pricing and margins.
Seeking Alpha Jul 03

HIMS Breakout Signals Structural Business Transformation

Summary The stock rebounded from below $14 after a regulatory shock and is now trading above $37 on a diversified growth narrative. Monthly weight-loss subscriber additions exceed one hundred thousand, transforming GLP-1 products into a powerful customer acquisition funnel. Peptides, AI healthcare systems, and international expansion create multi-layered optionality beyond traditional telehealth and pharmacy models. Elevated short interest near thirty percent could amplify upside if earnings and subscriber momentum continue accelerating further. Read the full article on Seeking Alpha

Recent updates

No updates